Vorinostat Combined with Third Generation Tkis to Overcome Egfr C797 Mutation in Lung Adenocarcinoma (II) = 利用Vorinostat與第三代酪胺酸激酶抑制劑聯合治療肺腺癌EGFR 點突變C797所造成的抗藥性 (2/3)

Project title

利用Vorinostat與第三代酪胺酸激酶抑制劑聯合治療肺腺癌EGFR 點突變C797所造成的抗藥性 (2/3)

Internal ID

109-2314-B-002-277-

Principal Investigator

Start Date

August 1, 2020

End Date

July 31, 2021

Partner Organizations

National Science and Technology Council